Domvanalimab

DB18848InvestigationalProtein Based Therapies

Domvanalimab is under investigation in clinical trial NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-small Cell Lung Cancer).

Mechanism: Pharmacologically active on T-cell immunoreceptor with Ig and ITIM domains
Curator reviewed
Also known as: Immunoglobulin g1 (236-alanine,237-alanine,de-c-terminal-lysine), anti-(human receptor tigit)(human-mus musculus monoclonal ab154 .gamma.1-chain), disulfide with human-mus musculus monoclonal ab154 .kappa.-chain, dimer
Code names: AB-154 · GS-0154

Resolves to

Compound

UNII45X7OU8C4JCAS2368219-35-4

Targets

Q495A1TIGIT

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

22Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Domvanalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account